COLLABORATION TO DEVELOP EVIDENCE-BASED STRATEGIES TO HELP IMPROVE OSTEOARTHRITIS MANAGEMENT Haleon and University of Sydney launch 5-Year fellowship to research efficacy of dietary supplements
SEGMENT
Filmed in Sydney and online | February 2025
INTERVIEWS
Professor David Hunter,
Florance and Cope Chair of Rheumatology
Co-Director Sydney Musculoskeletal Health Flagship,
University of Sydney
Dr Bincy Thampi,
Medical & Scientific Affairs Lead
Haleon ANZ
Osteoarthritis is a leading cause of disability affecting over 2 million Australians, according to Australian Institute of Health and Welfare report on Chronic musculoskeletal conditions (2024) and 595 million people globally, according to BD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020. It represents a significant public health burden that diminishes quality of life among ageing populations.
Consumer healthcare company Haleon is sponsoring a five-year named fellowship program at the University of Sydney that will investigate the therapeutic role of supplements in managing osteoarthritis symptoms and digital health technologies that improve mobility.
The fellowship will fund a postdoctoral researcher to work under the guidance of world leading osteoarthritis expert, rheumatologist and researcher Professor David Hunter.
Australian Health Journal spoke with Professor Hunter who said the research collaboration represents a shared focus and investment in improving osteoarthritis management: “This is a disabling disease that has a huge impact on the people affected.”
“A collaborative effort between researchers and manufacturers will drive innovation and hopefully improve the lives of those impacted by this devastating disease. Use of supplements and natural ingredients in managing osteoarthritis is an exciting area with a lot of potential. I’m not aware of any other long-term, five-year projects of this nature that has osteoarthritis as its focus,” said Hunter.
Haleon and the University of Sydney have a shared goal of finding better management strategies for osteoarthritis and developing better outcomes for the people affected.
Dr Bincy Thampi, Medical & Scientific Affairs Lead at Haleon ANZ, also spoke with Australian Health Journal and says, “Haleon has a strong commitment to scientific research that drives innovative self-care and improves consumer health outcomes.”
“This partnership illustrates Haleon’s commitment to advancing trusted science for our products to better everyday health and we’re excited to see where this partnership with University of Sydney leads,” said Dr Thampi.
-
Pharmacy led men’s urological health
Men’s urological needs refer to the medical and surgical conditions that affect the male urinary tract system and reproductive organs.
A urologist can address these concerns, however a pharmacy-led model of care developed by Brad Butt, called Mens Health Downunder has offered an alternative to certain urological needs of the male adult population over the past 10 years.
Australian Health Journal met with Brad to hear about his journey, Mens Health Downunder and the impact the pharmacy-led model of care has had on patient’s urological as well as mental health.
-
Impact of genetic pathologist role across medicine
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
-
Clinical Trials in Australia
Shanny Dyer, CEO ARCS Australia talks about a recent summit where the CRO (Contract Research Organization) community was asked on the current state of clinical trials in Australia.
